The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted how certain 340B hospitals could make initial drug purchases. The case challenged a provision in the rule involving group purchasing organizations, known as the “GPO prohibition,” which bars disproportionate share hospitals from simultaneously buying outpatient drugs through the 340B Drug Pricing Program and a GPO. Although the court set aside the existing GPO prohibition as unlawful, it sent the question back to the agency for reconsideration. “In that process,” the court explained, "HRSA may adopt the same bottom-line view of the statute it did in the 2013 Policy, as long as the agency adheres to the APA [Administrative Procedures Act] and does not exceed its limited rulemaking authority over the Section 340B Program.”

Headline
The AHA today voiced support () for the 340B Rebate Model Delay Act (H.R. 10770)in a letter to the bill’s House sponsors. The bipartisan bill would pause the…
Headline
The AHA, the Maine Hospital Association and four safety-net hospitals Oct. 9 filed a lawsuit in the U.S. District Court for the District of Maine challenging…
Headline
The AHA, the New Hampshire Hospital Association and 340B Health have filed an amicus brief supporting Mary Hitchcock Memorial Hospital’s request for a…
Headline
The Department of Health and Human Services’ Health Resources and Services Administration Oct. 1 announced approval of 10 drug companies to participate in the…
Headline
The Centers for Medicare & Medicaid Services’ 340B Part D claims data repository became available Oct. 1 for voluntary data submissions. While data…
Headline
The AHA Sept. 23 submitted comments on the Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act). The…